Clinical Medical Laboratory, Binzhou Medical University Hospital, Binzhou, 256603, P.R. China.
Cancer research institute, Binzhou Medical University Hospital, Binzhou, 256603, P.R. China.
Theranostics. 2019 Mar 17;9(7):2036-2055. doi: 10.7150/thno.32738. eCollection 2019.
Recent evidence indicates that UBE2C participates in carcinogenesis by regulating the cell cycle, apoptosis, metastasis, and transcriptional processes. Additionally, miR-548e-5p dysregulation plays a vital role in tumor progression. However, the molecular mechanism via which UBE2C is directly targeted by miR-548-5p, resulting in increase in cellular growth and invasiveness of cancer cells, and its interactions with the epithelial-mesenchymal transition (EMT) marker protein ZEB1/2 in non-small cell lung cancer (NSCLC) is not understood. Expression of UBE2C and miR-548e-5p was analyzed using reverse transcription-quantitative polymerase chain reaction (RT-qPCR). The protein level of UBE2C and ZEB1/2 was analyzed using western blotting and immunofluorescence staining. Cellular proliferation was detected using the cell counting kit 8 (CCK8) and 3-(4,5-dimethylthiazol-2-Yl)-2,5-diphenyltetrazolium bromide (MTT) assays. Cell migration, invasion, and growth were analyzed using the wound healing and transwell assay. Promoter activity and transcription was analyzed using the luciferase reporter assay. Chromatin immunoprecipitation was used to detect binding of UBE2C to 5'UTR-ZEB1/2. We observed that 4,5-ubiquitin-conjugating enzyme E2C () expression was higher in NSCLC tissue than in the adjacent normal tissue and was associated with increased cell proliferation and invasion. UBE2C enhanced NSCLC progression and metastasis by affecting the cell cycle and inhibiting apoptosis. We also observed that was significantly downregulated in lung cancer tissue specimens, which decreased the expression of its direct substrate, . Moreover, miR-548e-5p overexpression and UBE2C under-expression significantly suppressed lung cancer cell proliferation, migration, and invasion. Luciferase reporter and chromatin immunoprecipitation assays indicated that miR-548e-5p directly binds to the 3'-UTR of and decreases mRNA expression. Furthermore, knockdown downregulated the mesenchymal marker vimentin and upregulated the epithelial marker E-cadherin. Bioinformatics assays, coupled with western blotting and luciferase assays, revealed that UBE2C directly binds to the 5'-untranslated region (UTR) of the transcript of the E-cadherin repressor ZEB1/2 and promotes EMT in lung cancer cells. miR-548e-5p directly binds to the 3'-UTR of and decreases mRNA expression. is an oncogene that promotes EMT in lung cancer cells by directly targeting the 5'-UTR of the transcript encoding the E-cadherin repressor ZEB1/2. miR-548e-5p, UBE2C, and ZEB1/2 constitute the miR-548e-5p-UBE2C-ZEB1/2 signal axis, which enhances cancer cell invasiveness by directly interacting with e EMT marker proteins. We believe that the miR-548e-5p-UBE2C-ZEB1/2 signal axis may be a suitable diagnostic marker and a potential target for lung cancer therapy.
最近的证据表明,UBE2C 通过调节细胞周期、细胞凋亡、转移和转录过程参与致癌作用。此外,miR-548e-5p 失调在肿瘤进展中起着至关重要的作用。然而,UBE2C 如何被 miR-548e-5p 直接靶向,导致癌细胞的细胞生长和侵袭性增加,以及它与上皮-间充质转化(EMT)标记蛋白 ZEB1/2 在非小细胞肺癌(NSCLC)中的相互作用尚不清楚。使用逆转录定量聚合酶链反应(RT-qPCR)分析 UBE2C 和 miR-548e-5p 的表达。使用蛋白质印迹和免疫荧光染色分析 UBE2C 和 ZEB1/2 的蛋白水平。使用细胞计数试剂盒 8(CCK8)和 3-(4,5-二甲基噻唑-2-Yl)-2,5-二苯基四唑溴盐(MTT)测定法检测细胞增殖。使用划痕愈合和 Transwell 测定法分析细胞迁移、侵袭和生长。使用荧光素酶报告基因测定法分析启动子活性和转录。使用染色质免疫沉淀法检测 UBE2C 与 5'UTR-ZEB1/2 的结合。我们观察到,4,5-泛素连接酶 E2C () 在 NSCLC 组织中的表达高于相邻正常组织,与细胞增殖和侵袭增加有关。UBE2C 通过影响细胞周期和抑制细胞凋亡,增强 NSCLC 的进展和转移。我们还观察到,在肺癌组织标本中,显著下调,降低其直接底物的表达。此外,miR-548e-5p 的过表达和 UBE2C 的下调显著抑制肺癌细胞的增殖、迁移和侵袭。荧光素酶报告和染色质免疫沉淀实验表明,miR-548e-5p 可直接结合的 3'-UTR,并降低 mRNA 的表达。此外,下调间充质标记物波形蛋白并上调上皮标记物 E-钙粘蛋白。生物信息学分析,结合蛋白质印迹和荧光素酶实验,揭示 UBE2C 可直接结合转录物的 5'-UTR,并促进肺癌细胞中的 EMT。miR-548e-5p 可直接结合的 3'-UTR,并降低 mRNA 的表达。是一种癌基因,通过直接靶向编码 E-钙粘蛋白抑制剂 ZEB1/2 的转录物的 5'-UTR,促进肺癌细胞中的 EMT。miR-548e-5p、UBE2C 和 ZEB1/2 构成了 miR-548e-5p-UBE2C-ZEB1/2 信号轴,通过与 EMT 标记蛋白直接相互作用增强癌细胞的侵袭性。我们认为,miR-548e-5p-UBE2C-ZEB1/2 信号轴可能是一种合适的诊断标志物和肺癌治疗的潜在靶点。